Induction of effective CTL response was also coupled with homing of Survivin specific CTLs to the site of tumour in situ in melanoma and breast cancer [101] representing a complete synchronization of both local and systemic immune response when using Survivin as a vaccine candidate. The gene discussed is BIRC5; the disease is melanoma.